Last week in San Francisco, California, held the 39th Annual Meeting of the International Continence Society (ICS). The event attracted over 2,000 professionals in the fields of urology, gynaecology, uro-gynecology, physiotherapy, nursing, neurourology, anorectal surgery and paediatric urology.
Leading continence experts presented a rich scientific programme covering breakthroughs in science, research and medicine. Among the many incontinence treatments and studies presented at this year’s meeting one in specific draw the spotlight thanks to its effectiveness and quality of life improvements.
This minimally invasive device named Adjustable Continence Therapy (ACT) system proved to be an effective treatment for women with stress urinary incontinence associated with intrinsic sphincter deficiency.
The ACT bulks the bladder neck with adjustable silicone balloons providing urethral cooptation as well as bladder neck support. Each balloon is attached to a titanium port buried in the labia majora allowing for postoperative titration of the balloons for maximal efficacy.
So far, the tests were conducted in 162 patients who had the device implanted and have completed in some cases a 3 years follow-up where the results achieved impressive improvement in 83% of the patients.
The results shown that the Adjustable Continence Therapy (ACT) system is an effective and safe treatment for recurrent female stress urinary incontinence.